WeightWatchers Enhances Accessibility and Affordability of Weight Loss Medications with Compounded GLP-1

WeightWatchers Expands Offerings with Compounded Semaglutide

WeightWatchers (WW) has announced the inclusion of compounded semaglutide in its programs, enhancing access to clinical weight management solutions for eligible members. This initiative is backed by comprehensive, science-supported behavioral and lifestyle support that has been instrumental in helping millions achieve and maintain their weight goals.

“At WeightWatchers, we strive to blend proven scientific methods with personalized support to aid our members in achieving significant, lasting results. Our introduction of compounded semaglutide expands our offerings to include a clinical weight management solution that is both accessible and affordable,” said Tara Comonte, Interim CEO of WeightWatchers. “This launch reflects extensive research and our team’s commitment to providing the highest quality care, reinforcing the trust we have built over six decades as leaders in weight management.”

The market has experienced ongoing shortages of GLP-1 medications for over two years, leading to frequent unavailability of brand-name drugs in local pharmacies. In the past year, WeightWatchers conducted nearly 3 million stock checks on behalf of members across the country and found these medications in stock only 4.5% of the time. Such shortages can cause delays or interruptions in treatment, adversely affecting patient health outcomes.

“Given the persistent shortages of branded medications like Ozempic and Wegovy, WeightWatchers is dedicated to ensuring our members have access to effective alternatives and necessary support to achieve their desired health outcomes,” Comonte added.

In the last six months, about 45% of WeightWatchers Clinic members who were eligible for and prescribed a GLP-1 by their doctors encountered coverage denials from their insurance companies after three prior authorization requests. Less than 40% of insurers cover GLP-1 medications for weight loss, leaving many individuals with obesity without vital financial assistance. Among those with coverage, more than half reported that their GLP-1 medications remain difficult to afford.

“Compounded semaglutide can provide an important option for those pursuing weight loss support, particularly due to its greater availability and affordability,” said Dr. Jamil Alkhaddo, Medical Director of WeightWatchers. “In fact, over 50% of current members have expressed interest in a compounded GLP-1 for their weight loss journey. After thorough research and evaluation of various facilities, we have partnered with a reliable FDA-registered 503B facility that meets our high standards for quality and patient care, ensuring our eligible members can trust this new option as part of their weight loss plans.”

Compounding pharmacies can create medications that are identical or nearly identical to drugs that are on the FDA’s shortages list. WeightWatchers conducted a rigorous diligence process to select an FDA-registered 503B facility, which adheres to Current Good Manufacturing Practice (CGMP) regulations, the same standards enforced by the FDA for all manufacturing facilities producing FDA-approved drugs. Each batch of medication from a 503B facility is tested for sterility and potency to ensure safety and effectiveness.

“Patient safety and education are our top priorities. That’s why anyone prescribed a compounded GLP-1 medication will receive step-by-step guidance on its safe usage, along with access to one-on-one support from a trained clinician via telehealth appointments,” Dr. Alkhaddo said. “In addition to this new clinical solution, we remain dedicated to providing the personalized support our members expect throughout their journey. Each member can access a comprehensive care team, including insurance coordinators, registered dietitians, fitness coaches, and board-certified clinicians.”

WeightWatchers Clinic members benefit from integrated behavioral and lifestyle support, which is included in their subscription. This allows access to all WeightWatchers programs, including the GLP-1 Program, the Points® Program, and the Diabetes Program. This holistic support system, comprising workshops and a built-in community, is essential for achieving optimal health outcomes. Members using a GLP-1 medication alongside the behavioral Points® Program typically lose 11% more weight than those using weight loss medications alone.

Clinicians at WeightWatchers have the discretion to prescribe compounded semaglutide when deemed appropriate for a patient. Eligible members can choose to utilize their insurance for brand-name medications or opt for self-payment for compounded semaglutide. Only patients who meet specific clinical eligibility criteria will be prescribed a compounded GLP-1. If prescribed, members can expect delivery of their compounded semaglutide within 1-3 business days. They may also request a Certificate of Analysis (COA) for their medication, which ensures transparency regarding testing and quality standards maintained throughout the process.

WeightWatchers continues to provide a comprehensive care model, integrating accessible clinical solutions with science-backed behavioral programs, equipping members with the necessary tools and resources to achieve and sustain their weight health goals.